Phospholipids Trigger Cryptococcus Neoformans Capsular Enlargement During Interactions with Amoebae and Macrophages
Overview
Affiliations
A remarkable aspect of the interaction of Cryptococcus neoformans with mammalian hosts is a consistent increase in capsule volume. Given that many aspects of the interaction of C. neoformans with macrophages are also observed with amoebae, we hypothesized that the capsule enlargement phenomenon also had a protozoan parallel. Incubation of C. neoformans with Acanthamoeba castellanii resulted in C. neoformans capsular enlargement. The phenomenon required contact between fungal and protozoan cells but did not require amoeba viability. Analysis of amoebae extracts showed that the likely stimuli for capsule enlargement were protozoan polar lipids. Extracts from macrophages and mammalian serum also triggered cryptococcal capsular enlargement. C. neoformans capsule enlargement required expression of fungal phospholipase B, but not phospholipase C. Purified phospholipids, in particular, phosphatidylcholine, and derived molecules triggered capsular enlargement with the subsequent formation of giant cells. These results implicate phospholipids as a trigger for both C. neoformans capsule enlargement in vivo and exopolysaccharide production. The observation that the incubation of C. neoformans with phospholipids led to the formation of giant cells provides the means to generate these enigmatic cells in vitro. Protozoan- or mammalian-derived polar lipids could represent a danger signal for C. neoformans that triggers capsular enlargement as a non-specific defense mechanism against potential predatory cells. Hence, phospholipids are the first host-derived molecules identified to trigger capsular enlargement. The parallels apparent in the capsular response of C. neoformans to both amoebae and macrophages provide additional support for the notion that certain aspects of cryptococcal virulence emerged as a consequence of environmental interactions with other microorganisms such as protists.
Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance.
Su Y, Li Y, Yi Q, Xu Y, Sun T, Li Y J Fungi (Basel). 2025; 11(2).
PMID: 39997437 PMC: 11856953. DOI: 10.3390/jof11020143.
Role of the Anaphase-Promoting Complex Activator Cdh1 in the Virulence of .
Liao Q, Han L, Guo M, Fan C, Liu T J Fungi (Basel). 2024; 10(12).
PMID: 39728387 PMC: 11678062. DOI: 10.3390/jof10120891.
Clinical characteristics and prognostic factors of pulmonary and extrapulmonary cryptococcosis.
Tao Z, Pu Q, Shen Y, Zhang S, Wang C, Hu Z BMC Infect Dis. 2024; 24(1):1018.
PMID: 39304813 PMC: 11414175. DOI: 10.1186/s12879-024-09895-9.
Qu X, Bhalla K, Horianopoulos L, Hu G, Magana A, Foster L Front Fungal Biol. 2024; 5:1447588.
PMID: 39206133 PMC: 11349702. DOI: 10.3389/ffunb.2024.1447588.
Lee C, Brisland A, Qu X, Horianopoulos L, Hu G, Mayer F Front Cell Infect Microbiol. 2024; 14:1448229.
PMID: 39193507 PMC: 11347413. DOI: 10.3389/fcimb.2024.1448229.